Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527872 · ClinicalTrials.gov registry record
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
A clinical trial of Lupus Nephritis, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06527872 is a study of Lupus Nephritis that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 300 participants, roughly in line with the 300-participant average among 30 other Lupus Nephritis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06527872, a study of Lupus Nephritis, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
Conditions Studied
Interventions
- OTHER None (Observational study)
Study Locations (1)
North Carolina
- GSK Investigational Site - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2029-03-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06527872
The ClinicalTrials.gov registry entry for NCT06527872 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 300-participant average among 30 other Lupus Nephritis trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which None (Observational study) is the first listed.
NCT06527872 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06527872 about?
NCT06527872 is a clinical study titled "Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN". The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservatio...
What is the current status of trial NCT06527872?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-10-04. Estimated completion is 2029-03-29.
What conditions does trial NCT06527872 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT06527872?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT06527872?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527872 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.